Elevate your local knowledge
Sign up for the iNFOnews newsletter today!

THOUSAND OAKS, Calif. – Amgen Inc.’s fourth-quarter profit jumped 30 per cent due to higher sales for nearly all its drugs, an acquisition and a tax benefit.
The world’s biggest maker of biologic drugs says net income was $1.02 billion, or $1.33 per share, up from $788 million or per share a year earlier.
Excluding one-time items, Amgen says earnings amounted to $1.39 billion, or 1.82 per share. Analysts surveyed by FactSet were expecting $1.69 per share.
Revenue totalled $5.01 billion, up 13 per cent. Analysts expected $4.81 billion.
Sales were boosted by Amgen’s $9.7 billion purchase of Onyx Pharmaceuticals Inc. as part of Amgen’s strategy to become a major player in the market for pricey cancer drugs.
The company, based in Thousand Oaks, Calif., forecast 2014 adjusted earnings per share of $7.90 to $8.20.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.